

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
SATORI PHARMACEUTICALS INCORPORATED		10/01/2013	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	Lighthouse Capital Partners VI, L.P.		
Street Address:	3555 Alameda de las Pulgas, Ste 200		
Internal Address:	ATTN: CONTRACTS ADMINISTRATION		
City:	Menlo Park		
State/Country:	CALIFORNIA		
Postal Code:	94025		
Entity Type:	LIMITED PARTNERSHIP: DELAWARE		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Registration Number:	4027456	SATORI PHARMACEUTICALS	
Registration Number:	4027455	SATORI PHARMACEUTICALS	
CORRESPONDENCE DATA			
Fax Number:	6502330114		
	<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	650-233-1013		
Email:	graceg@lcpartners.com		
Correspondent Name:	Grace Gillen		
Address Line 1:	3555 Alameda de las Pulgas, Ste 200		
Address Line 2:	ATTN: CONTRACTS ADMINISTRATION		
Address Line 4:	Menlo Park, CALIFORNIA 94025		
ATTORNEY DOCKET NUMBER:	SATORI - TM		
NAME OF SUBMITTER:	Grace Gillen		

OP \$65.00 4027456

source=Intellectual Property Security Agmt 10.1.13 - Satori#page50.tif
source=Intellectual Property Security Agmt 10.1.13 - Satori#page51.tif

COLLATERAL ASSIGNMENT, PATENT MORTGAGE AND SECURITY AGREEMENT

This Collateral Assignment, Patent Mortgage and Security Agreement is made as of October 1, 2013 ("*Security Agreement*"), by and between Satori Pharmaceuticals Incorporated., a Delaware corporation ("*Debtor*"), and Lighthouse Capital Partners VI, L.P. ("*Lender*").

RECITALS

A. Lender has agreed to restructure funds lent to Debtor (collectively, the "*Loan*"), pursuant to the terms of a Amendment 05 to Loan and Security Agreement No. 1721 dated August 21, 2008 (as the same may be modified, amended, supplemented, restated or superceded from time to time, the "*Loan Agreement*"). Terms not defined herein shall the meanings ascribed to them in the Loan Agreement.

B. In order to induce Lender to restructure the Loan, Debtor has agreed to assign certain intangible property to Lender for purposes of securing the obligations of Debtor to Lender.

NOW, THEREFORE, the parties hereto agree as follows:

1. **ASSIGNMENT, PATENT MORTGAGE AND GRANT OF SECURITY INTEREST.** As collateral security for the prompt and complete payment and performance of all of Debtor's present or future indebtedness, obligations and liabilities to Lender, including, without limitation, such indebtedness, obligations and liabilities under the Loan Agreement and the other documents executed in connection therewith (as the same may be modified, amended, supplemented, restated or superceded from time to time, collectively, the "*Loan Documents*"), Debtor hereby assigns, transfers, conveys and grants a security interest and mortgage to Lender, as security, in and to Debtor's entire right, title and interest in, to and under the following, now or hereafter existing, created, acquired or held by Debtor (all of which shall collectively be called the "*Collateral*");

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, including, without limitation, those set forth on *Exhibit A* attached hereto and incorporated herein by this reference (collectively, the "*Copyrights*").

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products;

(c) Any and all design rights which may be available to Debtor;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including, without limitation, those set forth on *Exhibit B* attached hereto and incorporated herein by this reference (collectively, the "*Patents*");

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Debtor connected with and symbolized by such trademarks, including, without limitation, those set forth on *Exhibit C* attached hereto and incorporated herein by this reference (collectively, the "*Trademarks*");

(f) Any and all claims for damages by way of past, present and future infringement of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(g) All licenses or other rights to use any of the Copyrights, Patents or Trademarks, and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(h) All amendments, renewals and extensions of any of the Copyrights, Patents or Trademarks; and

(i) All proceeds and products of the foregoing, including, without limitation, all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

THE INTEREST IN THE COLLATERAL BEING ASSIGNED HEREUNDER SHALL NOT BE CONSTRUED AS A CURRENT ASSIGNMENT, BUT AS A CONTINGENT ASSIGNMENT TO SECURE ALL OF DEBTOR'S PRESENT OR FUTURE INDEBTEDNESS, OBLIGATIONS AND LIABILITIES TO LENDER, INCLUDING, WITHOUT LIMITATION, SUCH INDEBTEDNESS, OBLIGATIONS AND LIABILITIES UNDER THE LOAN AGREEMENT AND THE OTHER LOAN DOCUMENTS.

2. AUTHORIZATION AND REQUEST. Debtor authorizes and requests that the Register of Copyrights and the Commissioner of Patents and Trademarks record this conditional assignment.

3. COVENANTS AND WARRANTIES. Debtor represents, warrants, covenants and agrees as follows:

(a) Debtor is now the sole owner of the Collateral, except for non-exclusive licenses granted by Debtor to its customers in the ordinary and normal course of business as now conducted;

(b) Performance of this Security Agreement does not conflict with or result in a breach of any agreement to which Debtor is a party or by which Debtor is bound, except to the extent that certain intellectual property agreements prohibit the assignment of the rights thereunder to a third party without the licensor's or other party's consent and this Security Agreement constitutes an assignment;

(c) During the term of this Security Agreement, Debtor will not sell, transfer, assign or otherwise encumber any interest in the Collateral, except for (i) non-exclusive licenses granted by Debtor in the ordinary and normal course of its business as now conducted or as set forth in this Security Agreement and (ii) subject to Debtor's execution of appropriate documents, in form acceptable to Lender, to perfect or continue the perfection of Lender's interest in the Collateral, transfers to affiliates of Debtor;

(d) To its knowledge, each of the Patents is valid and enforceable, and no part of the Collateral has been judged invalid or unenforceable, in whole or in part, and no claim has been made that any part of the Collateral violates the rights of any third party;

(e) Debtor shall promptly advise Lender of any material changes in the composition of the Collateral, including but not limited to any subsequent ownership right of Debtor in or to any Copyright, Patent or Trademark not specified in this Security Agreement;

(f) Debtor shall (i) protect, defend and maintain the validity and enforceability of the Copyrights, Patents and Trademarks owned by Debtor, (ii) use its best efforts to detect infringements of the Copyrights, Patents and Trademarks owned by Debtor and promptly advise Lender in writing of material

infringements detected and (iii) not allow any Copyrights, Patents or Trademarks owned by Debtor to be abandoned, forfeited or dedicated to the public without the written consent of Lender, which shall not be unreasonably withheld, unless Debtor determines that reasonable business practices suggest that abandonment is appropriate;

(g) Debtor shall promptly register the most recent version of Debtor's material Copyrights, Patents and Trademarks owned by Debtor if not so already registered, as Lender may reasonably request from time to time based on its review of the Quarterly Report (as hereinafter defined) and shall, from time to time, execute and file such other instruments, and take such further actions as Lender may reasonably request from time to time to perfect or continue the perfection of Lender's interest in the Collateral;

(h) This Security Agreement creates, and in the case of after acquired Collateral, this Security Agreement will create at the time Debtor first has rights in such after acquired Collateral, in favor of Lender a valid and perfected first priority security interest in the Collateral in the United States securing the payment and performance of all present or future indebtedness, obligations and liabilities of Debtor to Lender, including, without limitation, such indebtedness, obligations and liabilities under the Loan Agreement and the other Loan Documents, upon making the filings referred to in Section 3(i) below, subject only to Permitted Liens;

(i) To its knowledge, except for, and upon, the filings with, as applicable, (1) the United States Patent and Trademark office with respect to the Patents and Trademarks, (2) the Register of Copyrights with respect to the Copyrights and (3) the UCC Division of the Delaware Secretary of State, necessary to perfect the security interests and assignment created hereunder, and except as has been already made or obtained, no authorization, approval or other action by, and no notice to or filing with, any United States governmental authority or United States regulatory body is required either (a) for the grant by Debtor of the security interest granted hereby or for the execution, delivery or performance of this Security Agreement by Debtor in the United States or (b) for the perfection in the United States or the exercise by Lender of its rights and remedies hereunder;

(j) All information heretofore, herein or hereafter supplied to Lender by or on behalf of Debtor with respect to the Collateral is accurate and complete in all material respects;

(k) Debtor shall not enter into any agreement that would materially impair or conflict with Debtor's obligations hereunder without Lender's prior written consent, which consent shall not be unreasonably withheld. Debtor shall not permit the inclusion in any material contract to which it becomes a party of any provisions that could or might in any way prevent the creation of a security interest in Debtor's rights and interests in any property included within the definition of the Collateral acquired under such contracts except for licenses and other rights identified in Section 3(g); and

(l) Upon any executive officer of Debtor obtaining actual knowledge thereof, Debtor will promptly notify Lender in writing of any event that materially adversely affects the value of any Collateral, the ability of Debtor to dispose of any Collateral or the rights and remedies of Lender in relation thereto, including the levy of any legal process against any of the Collateral.

4. LENDER'S RIGHTS. Lender shall have the right, but not the obligation, to take, at Debtor's sole expense, any actions that Debtor is required under this Security Agreement to take but which Debtor fails to take, after fifteen (15) days' notice to Debtor. Debtor shall reimburse and indemnify Lender for all reasonable costs and reasonable expenses incurred in the reasonable exercise of its rights under this Section 4.

5. INSPECTION RIGHTS. Debtor hereby grants to Lender and its employees, representatives and agent's the right to visit, during reasonable hours upon prior reasonable written notice to Debtor, any of Debtor's

plants and facilities that manufacture, install or store products (or that have done so during the prior six-month period) that are sold utilizing any of the Collateral, and to inspect the products and quality control records relating thereto upon reasonable written notice to Debtor and as often as may be reasonably requested.

6. FURTHER ASSURANCES; ATTORNEY IN FACT.

(a) On a quarterly basis, Debtor agrees to deliver to Lender a report, in form acceptable to Lender and certified by an officer of Debtor, which lists all Copyrights, Patents and Trademarks that are material to the operation of Debtor's business on an on-going basis, and in which Lender does not already have a perfected security interest (the "*Quarterly Report*"); *provided, however*, Debtor may provide a general description of the Copyrights by type. Based upon review of the Quarterly Report, Lender shall, in its reasonable discretion, identify which Copyrights, Patents and Trademarks it deems material to the operation of Debtor's business on an on-going basis or the value of the Collateral.

(b) On a continuing basis, Debtor will make, execute, acknowledge and deliver, and file and record in the proper filing and recording places in the United States, all such instruments, including appropriate financing and continuation statements and collateral agreements and filings with the United States Patent and Trademark Office and the Register of Copyrights, and take all such action as may reasonably be necessary or advisable, or as reasonably requested by Lender, to perfect Lender's security interest in all Copyrights, Patents and Trademarks, which Lender reasonably identifies pursuant to **Section 6(a)** above as material to the operation of Debtor's business on an on-going basis or the value of the Collateral, and otherwise to carry out the intent and purposes of this Security Agreement, or for assuring and confirming to Lender the grant or perfection of a security interest in all Collateral.

(c) Debtor hereby irrevocably appoints Lender as Debtor's attorney-in-fact, with full authority in the place and stead of Debtor and in the name of Debtor, from time to time in Lender's discretion, to take any action and to execute any instrument which Lender may reasonably deem necessary or advisable to accomplish the purposes of this Security Agreement, including (i) to modify, in its reasonable discretion, this Security Agreement without first obtaining Debtor's approval of or signature to such modification by amending Exhibit A, Exhibit B or Exhibit C hereof, as appropriate, to include reference to any material right, title or interest in any Copyrights, Patents or Trademarks acquired by Debtor after the execution hereof or to delete any reference to any right, title or interest in any Copyrights, Patents or Trademarks in which Debtor no longer has or claims any right, title or interest, (ii) to file, in its reasonable discretion, one or more financing or continuation statements and amendments thereto, relative to any of the Collateral without the signature of Debtor where permitted by law and (iii) after the occurrence and during the continuance of an Event of Default, to transfer the Collateral into the name of Lender or a third party to the extent permitted under the California Uniform Commercial Code.

7. EVENTS OF DEFAULT. The occurrence of any of the following shall constitute an "*Event of Default*" under this Security Agreement:

(a) An Event of Default occurs under the Loan Agreement or any of the other Loan Documents; or

(b) Debtor breaches any warranty or agreement in any material respect made by Debtor in this Security Agreement and, as to any breach that is capable of cure, Debtor fails to cure such breach within fifteen (15) days of the occurrence of such breach if notice thereof has been given to Debtor.

8. **REMEDIES.** Upon the occurrence and during the continuance of an Event of Default, Lender shall have the right to exercise all the remedies of a secured party under the California Uniform Commercial Code, including, without limitation, the right to require Debtor to assemble the Collateral and any tangible property in which Lender has a security interest and to make it available to Lender at a place designated by Lender. Lender shall have a nonexclusive, royalty free license to use the Copyrights, Patents and Trademarks to the extent reasonably necessary to permit Lender to exercise its rights and remedies upon the occurrence and during the continuance of an Event of Default. Debtor will pay any expenses (including reasonable attorneys' fees) incurred by Lender in connection with the exercise of any of Lender's rights hereunder, including, without limitation, any expense incurred in disposing of the Collateral. All of Lender's rights and remedies with respect to the Collateral shall be cumulative.

9. **INDEMNITY.** Debtor agrees to defend, indemnify and hold harmless Lender and its officers, employees, and agents (collectively with Lender, the "Lender Party") against: (a) all obligations, demands, claims, and liabilities claimed or asserted by any other party against any Lender Party in connection with the transactions contemplated by this Security Agreement and (b) all losses or expenses in any way suffered, incurred, or paid by any Lender Party as a result of or in any way arising out of, following or consequential to transactions between Lender and Debtor, under this Security Agreement (including, without limitation, reasonable attorneys' fees and reasonable expenses), except for losses arising from or out of the gross negligence or willful misconduct of Lender.

10. **REASSIGNMENT.** At such time as Debtor shall completely satisfy all of the obligations secured hereunder, or at such time that Debtor receives at least \$4,000,000 of additional equity investment, Lender shall execute and deliver to Debtor all deeds, assignments and other instruments as may be necessary or proper to revest in Debtor full title to the property assigned hereunder, subject to any disposition thereof which may have been made by Lender pursuant hereto.

11. **NO FAILURE OR DELAY.** No failure or delay on the part of Lender, in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof.

12. **ATTORNEYS' FEES.** If any action relating to this Security Agreement is brought by either party hereto against the other party, the prevailing party shall be entitled to recover reasonable attorneys' fees, costs and disbursements.

13. **AMENDMENTS.** This Security Agreement may be amended only by a written instrument signed by Lender.

14. **COUNTERPARTS.** This Security Agreement may be executed in any number of counterparts, each of which when so delivered shall be deemed an original, but all such counterparts shall constitute but one and the same instrument. Each such Security Agreement shall become effective upon the execution of a counterpart hereof or thereof by each of the parties hereto and telephonic notification that such executed counterparts has been received by Debtor and Lender.

15. **GOVERNING LAW; JURISDICTION; JURY WAIVER.** This Security Agreement shall be governed by, and construed in accordance with, the internal laws of the State of California, without regard to principles of conflicts of law. Debtor and Lender consent to the exclusive jurisdiction of any state or federal court located in San Francisco County, California. **DEBTOR AND LENDER EACH WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS SECURITY AGREEMENT AND ANY OTHER LOAN DOCUMENT OR ANY OF THE TRANSACTIONS**

CONTEMPLATED HEREIN, INCLUDING CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW OR STATUTORY CLAIMS.

16. **CONFLICT.** In the event of a conflict between any term and/or provision contained in this Security Agreement with any term and/or provision contained in any of the Loan Documents, the term and/or provision of this Security Agreement shall govern.

THIS SECTION INTENTIONALLY LEFT BLANK


IN WITNESS WHEREOF, the parties hereto have executed this Security Agreement on the day and year first above written.

DEBTOR:

LENDER:


SATORI PHARMACEUTICALS INCORPORATED

LIGHTHOUSE CAPITAL PARTNERS VI, L.P.

By: 

By: Lighthouse Management Partners VI, L.L.C.,
its general partner

Name: Edward T. Carino

By: 

Title: Wound Down Officer

Name: Ryan Turner
Managing Director

Title: _____

Exhibit A
COPYRIGHTS

1. **REGISTERED:** List titles below or indicate "None"

None

2. **UNREGISTERED:** List titles below or indicate "None"

None

3. **APPLICATIONS IN PROCESS:** List titles, applicable dates, application numbers, etc. below or indicate "None"

None

Exhibit B

U.S. PATENTS AND PATENT APPLICATIONS

Satori IP Summary Chart – updated September 23, 2013

PATENT FAMILY #1 - PATENT PORTFOLIO IN-LICENSED FROM MAYO

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
METHODS OF REDUCING BETA-AMYLOID POLYPEPTIDES (Pursuant to Satori - Mayo license.)	PARENT	US 09/804,420 Filed: 3/12/2001	Christopher Eckman Abdul Fauq Debra Yager Shari Haugabrook	Issued as US 6,649,196 on 11/18/2003.
	DIV	US 10/681,609 Filed: 10/8/2003	See above.	Abandoned.
	CON	US 11/241,573 Filed: 6/30/2005	See above.	Allowed/Granted.
	CON2	2006234-0006 US 11/876,653	See above.	Pending.

TRADEMARK

REEL: 005127 FRAME: 0132

PATENT FAMILY #1 - PATENT PORTFOLIO IN-LICENSED FROM MAYO

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
		Filed: 10/22/2007 2006234-0013		
	PARENT	PCT US02/07515 Filed: 3/12/2002 2006234-0005	See above.	Nationalized.
	NAT'L PHASE	EP 02723408.7 Filed: 10/13/2003 2006234-0004	See above.	Allowed/Granted.
		France	See above.	Allowed/Granted.

PATENT FAMILY #1 - PATENT PORTFOLIO IN-LICENSED FROM MAYO

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
		2006234-0068 (designated state)		

PATENT FAMILY #1 - PATENT PORTFOLIO IN-LICENSED FROM MAYO

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS			
					Germany 2006234-0069 (designated state)	See above.	Allowed/Granted.
					Ireland 2006234-0070 (designated state)	See above.	Allowed/Granted.
					Spain 2006234-0071 (designated state)	See above.	Allowed/Granted.
					Switzerland 2006234-0072 (designated state)	See above.	Allowed/Granted.
					United Kingdom	See above.	Allowed/Granted.

TRADEMARK

REEL: 005127 FRAME: 0135

PATENT FAMILY #1 - PATENT PORTFOLIO IN-LICENSED FROM MAYO

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
		2006234-0073 (designated state)		
	EP DIV	EP 10010348.0 2006234-0060	See above.	Pending.
		Hong Kong 2006234-0074	See above.	Pending.

PATENT FAMILY #2 - SATORI - SPI-014 AND RELATED COMPOUNDS

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS	PROV	US 60/681,662 Filed: 5/17/2005	Mark A. Findeis; Kolloi Pai; Frank Schroeder	Converted. US and PCT applications filed 5/16/06.
	PARENT	US 11/434,726 Filed: 5/16/2006 2006234-0007	See above.	Allowed/Granted.

TRADEMARK

REEL: 005127 FRAME: 0137

PATENT FAMILY #2 - SATORI - SPI-014 AND RELATED COMPOUNDS

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
	CON1	US 12/957,551 Filed: 5/16/2006	See above.	Pending.
	CON2	US 12/957,555 Filed: 5/16/2006	See above.	Pending.
	PARENT	PCT US06/19014 Filed: 5/16/2006	See above.	Nationalized.

TRADEMARK

REEL: 005127 FRAME: 0138

PATENT FAMILY #2 - SATORI - SPI-014 AND RELATED COMPOUNDS

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
		2006234-0008		
	AU	2006247244 Filed 5/16/2006 2006234-0016	See above.	Allowed/Granted.
	AU DIV1	2012211417 Filed 5/16/2006 2006234-0108	See above.	Pending.
	AU DIV2	2012211415 Filed 5/16/2006 2006234-0109	See above.	Pending.
	RU	2007148081 Filed 5/16/2006 2006234-0027	See above.	Allowed/Granted
	CA	2609021 Filed 5/16/2006	See above.	Allowed/Granted.

TRADEMARK

REEL: 005127 FRAME: 0139

PATENT FAMILY #2 - SATORI - SPI-014 AND RELATED COMPOUNDS

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
		2006234-0017		
	CN	200680025878.4 Filed 5/16/2006 2006234-0026	See above.	Pending.
	CN DIV	201210517453.2 Filed 5/16/2006 2006234-0122	See above.	Pending.
	EP	06770466.8 Filed 5/16/2006 2006234-0018	See above.	Pending
	HK	08109086.8 Filed 5/16/2006 2006234-0028	See above.	Pending.

PATENT FAMILY #2 - SATORI - SPI-014 AND RELATED COMPOUNDS

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
	IL	187439 Filed 5/16/2006 2006234-0024	See above.	Pending.
	IN	4497/KOLNP/200 Filed 5/16/2006 2006234-0023	See above.	Pending.
	JP	2008-512454 Filed 5/16/2006 2006234-0019	See above.	Allowed/Granted.
	JP DIV	Filed 5/16/2006 2006234-0123	See above.	Pending.
	KR	10-2007-7029349 Filed 5/16/2006 2006234-0025	See above.	Allowed/Granted.

PATENT FAMILY #2 - SATORI - SPI-014 AND RELATED COMPOUNDS

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
	MX	MX/2007/014465 Filed 5/16/2006 2006234-0020	See above.	Allowed/Granted.
	NZ	563888 Filed 5/16/2006 2006234-0021	See above.	Allowed/Granted.
	BR	PI0611528.4 Filed 5/16/2006 2006234-0022	See above.	Pending.
	CIP	US 11/602,073 Filed: 11/20/2006 2006234-0011	Mark Fideis	Abandoned.

PATENT FAMILY #2 - SATORI - SPI-014 AND RELATED COMPOUNDS

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
		US 12/640,262 CON Filed 12/17/09 2006234-0055	See above.	Pending.
		PCT US06/044880 Filed: 11/20/2006 2006234-0012	Mark Findeis	Nationalized.
	AU	2006350960 Filed 11/20/2006	See above.	Allowed/Granted.

PATENT FAMILY #2 - SATORI - SPI-014 AND RELATED COMPOUNDS

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
		2006234-0030		
	AU DIV	2013204450 Filed 11/20/2006 2006234-0125	See above.	Pending.
	BR	PI0622138-6 Filed 11/20/2006 2006234-0031	See above.	Pending.
	CA	2,670,276 Filed 11/20/2006 2006234-0032	See above.	Pending.
	CN	200680056874.2 Filed 11/20/2006	See above.	Abandoned.

PATENT FAMILY #2 - SATORI - SPI-014 AND RELATED COMPOUNDS

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
		2006234-0033		
	EP	06838050.0 Filed 11/20/2006 2006234-0034	See above.	Pending.
	IN	1928/KOLNP/2009 Filed 11/20/2006 2006234-0035	See above.	Pending.
	IL	198856 Filed 11/20/2006 2006234-0036	See above.	Pending.
	JP	2009-538376 Filed 11/20/2006 2006234-0037	See above.	Pending.

PATENT FAMILY #2 - SATORI - SPI-014 AND RELATED COMPOUNDS

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
	KR	10-2009-7012727 Filed 11/20/2006 2006234-0041	See above.	Pending.
	MX	mx/a/2009005351 Filed 11/20/2006 2006234-0038	See above.	Pending.
	NZ	577080 Filed 11/20/2006 2006234-0039	See above.	Abandoned.
	NZ DIV	599050 Filed 11/20/2006 2006234-0085	See above.	Abandoned.

PATENT FAMILY #2 - SATORI - SPI-014 AND RELATED COMPOUNDS

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
		RU 2009120038 Filed 11/20/2006 2006234-0040	See above.	Allowed/Granted.

PATENT FAMILY #3 - SATORI - BACKUP CORE STRUCTURE

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
MODULATORS OF AMYLOID-BETA PRODUCTION	PROV	US 60/860,130 Filed: 11/20/2006 2006234-0009	Mark Findeis Steffen Creaser	Converted. PCT application filed 11/20/2007.
	PARENT	PCT US07/85229 Filed: 11/20/2007 2006234-0014	See above.	Nationalized.
	NAT'L PHASE	US US 12/515,648 Filed: 5/20/09 2006234-0053	See above.	Abandoned.

TRADEMARK

REEL: 005127 FRAME: 0148

		US CON	US 13/550,125 Filed: 5/20/09 2006234-0086	See above.	Pending – To Be Abandoned.
		EP	07874499.2 Filed: 3/27/09 2006234-0043	See above.	Abandoned.

PATENT FAMILY #4 - SATORI - SEMI-SYNTHESIS OF SPI-014 AND RELATED COMPOUNDS

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
SYNTHESIS OF COMPOUNDS USEFUL AS MODULATORS OF AMYLOID-BETA PRODUCTION	PROV	US 60/860,185 Filed: 11/20/2006.	Mark Findeis	Converted.
	PARENT	PCT/US07/85161 Filed 11/20/07 2006234-0015	See above.	Nationalized.
	NAT'L PHASE	AU 2007352555 Filed: 5/20/09	See above.	Allowed/Granted.

TRADEMARK

REEL: 005127 FRAME: 0150

		2006234-0048			
CA	2670284 Filed: 5/20/09 2006234-0049	See above.	Allowed/Granted.		
EP	07874299.6 Filed: 5/20/09 2006234-0044	See above.	Allowed/Granted.		
SZ	2006234-0127	See above.	Allowed/Granted.		
DE	2006234-0128	See above.	Allowed/Granted.		
GB	2006234-0129	See above.	Allowed/Granted.		
IN	1937/KOLNP/2 009 Filed: 5/20/09 2006234-0050	See above.	Pending.		
IL	198855 Filed: 5/20/09	See above.	Pending.		

		2006234-0051		
NZ	577081 Filed: 5/20/09	2006234-0052	See above.	Allowed/Granted.
NZ DIV	598280 Filed: 5/20/09	2006234-0084	See above.	Abandoned.
NZ DIV2	614369 Filed: 5/20/09	2006234-0126	See above.	Pending.
US	12/515703 Filed: 5/20/09	2006234-0054	See above.	Allowed/Granted.
US CON	13/566201 Filed: 5/20/09	2006234-0107	See above.	Abandoned.

PATENT FAMILY #5 - SATORI – COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS	PROV	US 61/310,152 Filed: 3/3/10 2006234-0042	Brian Scott Bronk, Wesley Francis Austin, Steffen Phillip Greaser, Mark A. Findels, Nathan Oliver Fuller, Jed Lee Hubbs and Jeffrey Lee Ives	Converted.
	PARENT US	USSN 13/040,166 Filed: 3/3/11	Brian Scott Bronk, Wesley Francis Austin, Steffen Phillip	Abandoned.

TRADEMARK

REEL: 005127 FRAME: 0153

PATENT FAMILY #5 - SATORI – COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS

		2006234-0063	Greaser, Mark A. Findels, Nathan Oliver Fuller, Jed Lee Hubbs and Jeffrey Lee Ives, Ruichao Shen	
US CON	USSN 14/021,576 Filed: 9/9/2013 2006234-0130	See above.		Pending.
AR	No. P110100671 Filed: 3/3/11 2006234-0065	See above.		Pending.
TW	No. 100107238 Filed: 3/3/11 2006234-0066	See above.		Pending.

TRADEMARK

REEL: 005127 FRAME: 0154

PATENT FAMILY #5 - SATORI -- COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS

VE	No. 2011-000269 Filed: 3/4/11 2006234-0067	See above.	Pending.
PARENT	PCT/US11/27084 Filed: 3/3/11 2006234-0064	See above.	Nationalized.
PCT			
AU	2011223542 Filed: 3/3/11 2006234-0110	See above.	Pending.
BR	BR1120120222 Filed: 3/3/11 2006234-0111	See above.	Pending.
CA	2,790,060 Filed: 3/3/11	See above.	Pending.

TRADEMARK

REEL: 005127 FRAME: 0155

PATENT FAMILY #5 - SATORI – COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS

	2006234-0112			
CN	11751383.8 Filed: 3/3/11 2006234-0113	See above.		Pending.
EP	11751383.8 Filed: 3/3/11 2006234-0114	See above.		Pending.
IL	221415 Filed: 3/3/11 2006234-0115	See above.		Pending.
IN	7429/DELNP/20 12 Filed: 3/3/11 2006234-0116	See above.		Pending.

PATENT FAMILY #5 - SATORI - COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS

			2006234-0121	
--	--	--	--------------	--

PATENT FAMILY #6 - SATORI – COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS	PROV	USSN 61/532,049 Filed: 9/7/11 2006234-0076	Brian Scott Bronk, Wesley Francis Austin, Steffen Phillip Creaser, Nathan Oliver Fuller, Jed Lee Hubbs, Jeffrey Lee Ives, Ruichao Shen	Converted.
	PARENT US	USSN 13/605,956 Filed: 09/06/2012 2006234-0087	See above.	Pending.

TRADEMARK

REEL: 005127 FRAME: 0159

	PARENT PCT	PCT/US12/54022 Filed: 9/6/12 2006234-0088	See above.	Pending.
--	-----------------------	--	------------	----------

**PATENT FAMILY #7 - SATORI – COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS,
SYNTHESIS THEREOF, AND INTERMEDIATES THERETO**

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
COMPOUNDS FOR USE IN TREATING NEURODEGENERATIVE DISORDERS, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO	PROV	USSN 61/532,051 Filed: 9/7/11 2006234-0077	Brian Scott Bronk, Wesley Francis Austin, Steffen Phillip Creaser, Nathan Oliver Fuller, Jed Lee Hubbs, Ruichao Shen	Converted.
	PARENT US	USSN 13/605,961 Filed: 9/6/12	See above.	Pending.

TRADEMARK

REEL: 005127 FRAME: 0161

		2006234-0089			
PARENT PCT		PCT/US12/53997 Filed: 9/6/12 2006234-0090	See above.		Pending.
AR		No. P.120103281 Filed: 9/6/12 2006234-0091	See above.		Pending.
TW		No. 101132585 Filed: 9/6/12 2006234-0092	See above.		Pending.
VE		No. 2012-001130 Filed: 9/6/12 2006234-0093	See above.		Pending.

PATENT FAMILY #8 - SATORI – COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS	PROV	USSN 61/532,057 Filed: 9/7/11 2006234-0079	Brian Scott Bronk, Wesley Francis Austin, Steffen Phillip Creaser, Nathan Oliver Fuller, Jed Lee Hubbs and Jeffrey Lee Ives, Ruichao Shen	Converted.
	PARENT US	USSN 13/605,965 Filed: 9/6/12	See above.	Pending.

TRADEMARK

REEL: 005127 FRAME: 0163

		2006234-0094			
PARENT PCT	PCT/US12/54002 Filed: 9/6/12	2006234-0095	See above.		Pending.
AR	No. P120103282 Filed: 2006234-0096		See above.		Pending.
TW	No. 101132586 Filed: 2006234-0097		See above.		Pending.
VE	No. 2012-001131 Filed: 2006234-0098		See above.		Pending.

PATENT FAMILY #9 - SATORI - COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS	PROV	USSN 61/532,055 Filed: 9/7/11 2006234-0080	Brian Scott Bronk, Wesley Francis Austin, Steffen Phillip Creaser, Nathan Oliver Fuller, Jed Lee Hubbs and Jeffrey Lee Ives, Ruichao Shen	Converted.
	PARENT US	USSN 13/605,973 Filed: 9/6/12	See above.	Pending.

TRADEMARK

REEL: 005127 FRAME: 0165

		2006234-0099			
	PARENT PCT	PCT/US12/54013 Filed: 9/6/12	See above.		Pending.
		2006234-0100			

PATENT FAMILY #10 - SATORI – COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS	PROV	USSN 61/532,053 Filed: 9/7/11 2006234-0081	Brian Scott Bronk, Wesley Francis Austin, Steffen Phillip Creaser, Nathan Oliver Fuller, Jed Lee Hubbs and Jeffrey Lee Ives, Ruichao Shen	Converted.
	PARENT US	USSN 13/605,978 Filed: 9/6/12	See above.	Pending.

		2006234-0101		
	PARENT PCT	PCT/US12/54011 Filed: 9/6/12	See above.	Pending.
		2006234-0102		

PATENT FAMILY #11 - SATORI – COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS	PROV	USSN 61/532,059 Filed: 9/7/11 2006234-0082	Brian Scott Bronk, Wesley Francis Austin, Steffen Phillip Creaser, Nathan Oliver Fuller, Jed Lee Hubbs and Jeffrey Lee Ives, Ruichao Shen	Converted.
	PARENT US	USSN 13/605,970 Filed: 9/6/12	See above.	Pending.

		2006234-0103		
PARENT PCT	PCT/US12/54007 Filed: 9/6/12	2006234-0104	See above.	Pending.

PATENT FAMILY #12 - SATORI – COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS

TITLE	APPLN TYPE	COUNTRY	INVENTORS	STATUS
COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS	PROV	USSN 61/532,048 Filed: 9/7/11 2006234-0083	Brian Scott Bronk, Wesley Francis Austin, Steffen Phillip Creaser, Nathan Oliver Fuller, Jed Lee Hubbs and Jeffrey Lee Ives, Ruichao Shen	Converted.
	PARENT US	USSN 13/605,968 Filed: 9/6/12	See above.	Pending.

		2006234-0105		
PARENT PCT		PCT/US12/54004 Filed: 9/6/12	See above.	Pending.
		2006234-0106		

Exhibit C

U.S. TRADEMARKS AND TRADEMARK APPLICATIONS

(List marks below or indicate "None")

Country	Registration No.	Pending Application No.	Mark	Registration Date	Filing Date
US FILINGS:					
US	4,027,455	77/844,711	SATORI PHARMACEUTICALS	9/10/2011	10/8/2009
US	4,027,456	77/844,738	SATORI PHARMACEUTICALS & Design	9/20/2011	10/8/2009
FOREIGN FILINGS:					

UNREGISTERED TRADEMARKS: List marks below or indicate "None."

None